News AZ's Lynparza becomes first PARP drug approved in breast can... Lynparza first in class approved in breast cancer
News Clovis PARP drug gets fast US review in new ovarian cancer u... Impressed by survival data, FDA hastens review in expanded patient group
News Tesaro gets European approval on Zejula, set to challenge AZ Tesaro's PARP drug approved in wider ovarian cancer population
News Tesaro's Zejula primed for EU approval, battle with AZ EU regulators recommend PARP inhibitor Zejula
News Trump tax reform uncertainty puts biotech M&A on hold Tesaro and Puma are potential takeover targets
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
